Nicole Cuellar-Kingston  
Cargill, Incorporated  
15407 McGinty Road West, M.S. 163  
Wayzata, MN 55391  

Re: GRAS Notice No. GRN 000867

Dear Ms. Cuellar-Kingston:

The Food and Drug Administration (FDA) is granting the request to cease our evaluation of GRN 000867, which we filed on July 9, 2019. We received this request on August 19, 2019.

The subject of the notice is rebaudioside M from *Yarrowia lipolytica* (rebaudioside M) for use as a general-purpose sweetener in foods, excluding infant formula and meat and poultry products, at levels determined by good manufacturing practices. The notice informs us of Cargill, Incorporated (Cargill)'s view that these uses of rebaudioside M are GRAS through scientific procedures.

On July 22, 2019, Cargill submitted an amendment consisting of a replacement of the original notice with a new notice. We informed you by email on July 29, 2019, about our determination that the replacement submission is deemed as a new notice and, as such, a new GRAS submission process needs to be followed; to follow a new GRAS submission process, Cargill asks us to cease to evaluate GRN 000867 and will resubmit their new version at a later time. On August 12, 2019, we held a teleconference to discuss the matter with Cargill. In an email dated August 19, 2019, Cargill requested that we cease our evaluation of GRN 000867, stating that Cargill has identified technical language in the notice that warrants clarification in order to avoid confusion.

In accordance with 21 CFR 170.275(b)(3), the text of this letter responding to GRN 000867 is accessible to the public at www.fda.gov/grasnoticeinventory.

Sincerely,

Susan Carlson, Ph.D.  
Director  
Division of Food Ingredients  
Office of Food Additive Safety  
Center for Food Safety and Applied Nutrition